Scholar Rock Holding Corporation (SRRK) Stock Score, Valuation & Financial Research

Scholar Rock Holding Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SRRK

Scholar Rock Holding Corporation does not currently have a complete Wall Street Score. The stored market price is USD 47.70. These figures are a research snapshot, not a buy or sell recommendation.

What Scholar Rock Holding Corporation does

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Scholar Rock is a clinical-stage biopharmaceutical company that generates no product revenue as of the 2025 fiscal year-end. Its business model relies on raising capital through equity offerings and debt to fund the research, development, and clinical testing of its proprietary anti-myostatin platform and product candidates, such as apitegromab, with the goal of future commercialization.

Products and services

  • The company is developing a pipeline of protein-based therapeutics targeting myostatin, including its lead candidate apitegromab for spinal muscular atrophy (SMA) and SRK-439 for other neuromuscular disorders.

Brands and product families

  • Apitegromab — Lead product candidate for the treatment of spinal muscular atrophy. Source
  • SRK-439 — Product candidate for neuromuscular disorders. Source

Customer types

Patients with spinal muscular atrophy (SMA); Patients with other neuromuscular disorders.

Suppliers, materials and equipment

  • Contract manufacturing organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary platform in myostatin biology Source
  • Intellectual property portfolio Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Regulatory risks and potential for clinical trial delays or failures Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SRRK financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 47.70
Market capitalization:
5.72B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -408.59M
Free cash flow:
USD -300.64M
Cash:
USD 437.09M
Total debt:
USD 203.83M
EPS:
USD -3.31

What stands out

  • Free cash flow is USD -300.64M, negative for the stored period.
  • The balance sheet shows USD 437.09M of cash versus USD 203.83M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 233.26M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SRRK

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SRRK fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SRRK likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SRRK to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SRRK's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SRRK

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.